Duke Suit Vs. Elan Targets Competing Patent Filings

Law360, New York (July 6, 2004, 12:00 AM EDT) -- Duke University has sued drug maker Elan Corp. over competing patents for a promising obesity drug.

Duke’s lawsuit, filed last month in U.S. District Court in Durham, North Carolina, accuses Elan of fraud, copyright infringement and unfair competition.

Duke is joined in the suit by Orexigen Therapeutics, a Princeton, a licensee for certain university technology.

Also named as a defendant is Eisai Ltd., the Japanese drug company that bought the rights to the drug and the associated patent application.

Duke has asked the court to declare...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.